HighTide Therapeutics, Inc.
Research HighTide Therapeutics, Inc. (2511.HK) on Bullrun: market cap HKD 1.88B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2511.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 1.88B
- Financial periodFY2025
- RevenueCNY 0
- Net income-CNY 232.10M
- Free cash flow-CNY 166.98M
Valuation Snapshot
latest market cap is HKD 1.88B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 0 | -CNY 232.10M | -CNY 166.98M | n/a | -0.51 | CNY 232.39M | CNY 126.87M | CNY 307.01M |
| FY2024 | CNY 0 | -CNY 381.79M | -CNY 302.75M | n/a | -0.84 | CNY 310.75M | CNY 77.91M | CNY 424.17M |
| FY2023 | CNY 0 | -CNY 939.31M | -CNY 357.42M | n/a | -3.62 | CNY 608.21M | CNY 16.43M | CNY 702.77M |
| FY2022 | CNY 0 | -CNY 190.24M | -CNY 172.56M | n/a | -0.75 | CNY 412.34M | CNY 10.77M | -CNY 470.53M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 1.88B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About HighTide Therapeutics, Inc.
HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies to treat patients with chronic metabolic and liver diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase III clinical trial to treat type 2 diabetes mellitus (T2DM); in phase I clinical trial to treat gradual loss of kidney function over time; phase IIb for the treatment of pathogenetic complexity and heterogeneity; phase I to treat obesity;
ETFs that hold HighTide Therapeutics, Inc.
US-listed ETFs
HighTide Therapeutics, Inc. is held by 2 US-listed ETFs, going by the latest portfolios they filed with the SEC, most traded first:
| ETF | Weight | Fee |
|---|---|---|
| State Street SPDR S&P China ETF (GXC) | 0.01% | 0.59% |
| State Street SPDR S&P Emerging Markets Small Cap ETF (EWX) | 0.01% | 0.65% |
Portfolios as filed with the SEC on Form N-PORT, dated June 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is HighTide Therapeutics, Inc.'s market cap?
HighTide Therapeutics, Inc.'s market capitalization is HKD 1.88B.
What does HighTide Therapeutics, Inc. do?
HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies to treat patients with chronic metabolic and liver diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase III clinical trial to treat type 2 diabetes mellitus (T2DM); in phase I clinical trial to treat gradual loss of kidney function over time; phase IIb for the treatment of pathogenetic complexity and heterogeneity; phase I to treat obesity; and phase II for the treatment of chronic cholestatic liver disease.